BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230509
DTEND;VALUE=DATE:20230512
DTSTAMP:20260516T055807
CREATED:20230227T131842Z
LAST-MODIFIED:20230227T131842Z
UID:36691-1683590400-1683849599@www.pharmajournalist.com
SUMMARY:4th STING & TLR Targeting Therapies Summit
DESCRIPTION:Facilitating key conversations needed to drive forward the development of safe and effective innate stimulating immunotherapies\, the 4th STING & TLR Targeting Therapies Summit will take place\, for the first time ever in person\, in Boston on May 9-11\, 2023. \nView the official program here. \nExplore innate agonists from discovery to translation with the leaders in the space and gain insight into clinical updates\, unpack what went wrong with some failures like ADU-S100 and address critical challenges including driving down toxicity\, preclinical model selection and choosing appropriate delivery mechanisms. \nHere are some exciting highlights you cannot miss including: \n\nReviewing the clinical landscape in the past year\, key updates in innate agonists that have moved through the clinic\, and identifying the root of failed trials through integral discussions led by Beacon Targeted Therapies\, Tempest Therapeutics\, and #Indaptus Therapeutics\nAssessing the best innate agonist delivery approaches\, from data on antibody-conjugated STING agonists with Takeda Oncologyand ImmuneSensor to unpacking 7&8 Biopharma’s IV delivery to extracellular vesicle approaches with Codiak Bio \nRevisiting cancer vaccines and navigating their development with post-COVID vaccine considerations; with Elicio Therapeuticsand UT Southwestern Medicine\, exploring the use of STING / TLR adjuvants to deliver on this promising therapeutic\nVenturing beyond oncology to learn from drug developers utilizing STING & TLR agonists to treat infectious diseases and adding these potent innate activators to our arsenal to be better equipped for the next pandemic\n\nView the complete agenda and speaker line-up. \nBeing the only meeting dedicated to driving forward the development of innate immune agonists\, we encourage you to take this exciting opportunity to unite and leverage the industry’s cumulative knowledge and experience to have meaningful conversations that will translate STING & TLR agonists into effective and reliable treatment options.
URL:https://www.pharmajournalist.com/event/4th-sting-tlr-targeting-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR